ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidin e), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 3, 2000, Pages 1156-1164

  Jarvis, Michael F ^a   Yu, Haixia ^a   Kohlhaas, Kathy ^a   Alexander, Karen ^a   Lee, Chih Hung ^a   Jiang, Mequin ^a   Bhagwat, Shripad S ^a,b   Williams, Michael ^a   Kowaluk, Elizabeth A ^a  

^a ABBOTT LABORATORIES   (United States)

^b Signal Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 AMINO 5 (3 BROMOPHENYL) 7 (6 MORPHOLINOPYRIDIN 3 YL)PYRIDO[2,3 D]PYRIMIDINE; 8 (4 SULFOPHENYL)THEOPHYLLINE; ABT 702; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTINOCICEPTIVE AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; MORPHINE; NALOXONE; PHENYLQUINONE; THEOPHYLLINE; THEOPHYLLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HOT PLATE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE KINASE; ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MALE; MICE; MORPHOLINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1;

EID: 0033680092     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. The control of the metabolism and the hormonal role of adenosine
2. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erthroleukemia (K562) cells
3. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
4. Site and event specific increase of striatal adenosine release by adenosine kinase inhibition in rats
5. New adenosine kinase inhibitors with oral antiflammatory activity: Synthesis and biological evaluation
6. Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: Pharmacological activities and potent inhibition of adenosine kinase
7. Intrinsic tryptophan fluoresence of bovine Ever adenosine kinase, characterization of ligand binding sites and conformational changes
8. Adenosine kinase inhibitors augument release of adenosine from spinal cord slices
9. Inhibition of acid sialidase by inorganic sulfate
10. Adenosine kinase from human erthrocytes: Kinetic studies and characterization of adenosine binding sites
11. Characterization of the antinociceptive effects of some adenosine analogues in the rat
12. 2 receptors in rat brain tissue
13. Adenosine kinase inhibition protects brain against transient focal ischemia in rats
14. Spinally mediated antinociception is induced in mice by an adenosine kinase, but not an adenosine deaminase inhibitor
15. Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice
16. Therapeutic potential of adenosine kinase inhibitors
17. Exogenous and endogenous adenosine enhance the spinal antiallodynic effects of morphine in a rat model of neuropathic pain
18. Regulation of adenosine kinase by adenosine analogs
19. Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques
20. Structure of human adenosine kinase at 1.5A resolution
21. Cloning and expression of the adenosine kinase gene from rat and human tissues
22. Pre- and peristroke treatment with the adenosine kinase inhibitor, 5'deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats
23. Turnover of adenosine in plasma of human and dog blood
24. Acadesine: Prototype adenosine regulating agent for treating myocardial ischemia-reperfusion injury
25. The control of adenosine concentration in polymorphonuclear leukocytes, cultured cells and isolated perfused heart from the rat
26. Adenosine and the concept of 'retaliatory metabolites'
27. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices
28. Human placental adenosine kinase, kinetic mechanism and inhibition
29. Antinociception by adenosine analogs and an adenosine kinase inhibitor: Dependence on formalin concentration
30. Receptors for purines and pyrimidines
31. Peripheral antinociceptive effect of an adenosine kinase inhibitor with augmentation by an adenosine deaminase inhibitor, in the rat formalin test
32. 3,7-Dimethyl-1-propargylxanthine: A potent and selective in vivo antagonist of adenosine analogs
33. Cloning of human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases
34. Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition and antiseizure activity of diaryltubercidin analogues
35. The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs
36. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy
37. Purinergic and pyrimidinergic receptors as potential drug targets
38. Adenosine: The prototypical modulator
39. Purification and properties of adenosine kinase from rat brain
40. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility